# Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience.

## üìù Summary (Korean)
This study is about Cancer. Treatment Method research. Providing new insights through Utilized patient data.

## Paper Information
- **Title**: Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium 223: Princess Margaret Cancer Centre (PMCC) experience.
- **Authors**: Esmail M Al-Ezzi, Osama Abdeljalil, Katherine Lajkosz, Shreya S Gramolini, Husam Alqaisi, Jenny Peng, Richard Odwyer, Mohammed Alghamdi, Sulaiman Almuthri, Vikaash Kumar, Di Maria Jiang, Nazanin Fallah-Rad, Neil Fleshner, Srikala S Sridhar
- **Journal**: Urologic oncology
- **Publication Date**: 2025-07-08
- **DOI**: 10.1016/j.urolonc.2025.06.004
- **PMID**: 40634195
- **PMC ID**: 
- **Keywords**: HRD, Prostate cancer, Radium 223, Survival outcomes

## Abstract
BACKGROUND: Radium-223 ( METHODS: This retrospective analysis was performed in men with mCRPC and bone metastases, with and without HRD, treated with androgen deprivation therapy (ADT) and RESULTS: Between 2015 and 2022, we identified 40 mCRPC patients who underwent CONCLUSIONS: Despite the small size, these findings suggest that patient with HRD may have a slight improvement in survival outcomes after

## Collection Information
- **Collection Date**: 2025-07-15 09:46:59
- **Search Keywords**: germline
- **Keyword Matching Score**: 0.25
- **Relevance Category**: low
- **PubMed URL**: https://pubmed.ncbi.nlm.nih.gov/40634195/

## Metadata
- **Language**: eng
- **Publication Type**: Journal Article
- **MeSH Terms**: 
- **Grant Information**: 

---
*This document was automatically generated by Paper Surfer.*
